The effects of metformin on ovarian cancer: A systematic review

Dilokthornsakul, Piyemeth, Chaiyakunapruk, Nathorn, Termrungruanglert, Wichai, Pratoomsoot, Chayanin, Saokeaw, Surasak and Sruamsiri, Rosarin (2013) The effects of metformin on ovarian cancer: A systematic review. International Journal of Gynecological Cancer, 23 9: 1544-1551. doi:10.1097/IGC.0b013e3182a80a21

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Dilokthornsakul, Piyemeth
Chaiyakunapruk, Nathorn
Termrungruanglert, Wichai
Pratoomsoot, Chayanin
Saokeaw, Surasak
Sruamsiri, Rosarin
Title The effects of metformin on ovarian cancer: A systematic review
Journal name International Journal of Gynecological Cancer   Check publisher's open access policy
ISSN 1048-891X
1525-1438
Publication date 2013-11-01
Sub-type Article (original research)
DOI 10.1097/IGC.0b013e3182a80a21
Volume 23
Issue 9
Start page 1544
End page 1551
Total pages 8
Place of publication New York, NY, United States
Publisher Lippincott Williams & Wilkins
Language eng
Formatted abstract
Objective: The potential therapeutic effects of metformin on several cancers were reported. However, the evidence of the effects of metformin on ovarian cancer is still limited and inconclusive. This systematic review and meta-analysis study aims to summarize the existing evidence of the therapeutic effects of metformin on ovarian cancer.

Methods: We performed systematic searches using electronic databases including PubMed and EMBASE until December 2012. Key words included “metformin” AND (“ovarian cancer” OR “ovary tumor”). All human studies assessing the effects of metformin on ovarian cancer were eligible for inclusion. All articles were reviewed independently by 2 authors with a standardized approach for the purpose of study, study design, patient characteristics, exposure, and outcomes. The data were pooled using a random-effects model.

Results:
Of 190 studies retrieved, only 3 observational studies and 1 report of 2 randomized controlled trials were included. Among those studies, 2 reported the effects of metformin on survival outcomes of ovarian cancer, whereas the other 2 reported the effects of metformin on ovarian cancer prevention. The findings of studies reporting the effects on survival outcomes indicated that metformin may prolong overall, disease-specific, and progression-free survival in ovarian cancer patients. The results of studies reporting the effects of metformin on ovarian cancer prevention were meta-analyzed. It indicated that metformin tended to decrease occurrence of ovarian cancer among diabetic patients with the pooled odds ratio of 0.57 (95% confidence interval, 0.16–1.99).

Conclusions:
Our findings showed the potential therapeutic effects of metformin on survival outcomes of ovarian cancer and ovarian cancer prevention. However, most of the evidence was observational studies. There is a call for further well-conducted controlled clinical trials to confirm the effects of metformin on ovarian cancer survival and ovarian cancer prevention.
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2014 Collection
School of Public Health Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 19 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 22 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 18 Nov 2013, 21:44:26 EST by Dr Anna D MacDonald (nee Holmes) on behalf of School of Public Health